Provectus Biopharmaceuticals Releases 2023 Stockholder Letter
09 janv. 2023 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found...
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
10 nov. 2022 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
10 nov. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
11 oct. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
15 août 2022 08h10 HE
|
Vaccinex, Inc.
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in...
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
16 mai 2022 08h15 HE
|
Vaccinex, Inc.
Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck...
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
09 mars 2022 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
The Worldwide Merkel Cell Carcinoma Disease Treatment Industry is Expected to Reach $3.7 Billion by 2026
01 mars 2022 07h08 HE
|
Research and Markets
Dublin, March 01, 2022 (GLOBE NEWSWIRE) -- The "Merkel Cell Carcinoma Disease Treatment Market - Forecast 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The Merkel cell...
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
26 janv. 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
06 janv. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...